metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	avelumab plus axitinib
	JAVELIN Renal 101 (all population), 2019 N. Engl. J. Med. 2019; 380:1103-1115 Cancer Sci. 2020; 111:907-923 Nat Med 2020 Sep 7. Ann Oncol 2020 Aug;31(8):1030-1039. ESMO Open 2021 Apr 23;6(3):100101. ESMO Open . 2022 Apr;7(2):100450 NCT02684006	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	Avelumab plus Axitinib	Sunitinib	patients with previously untreated advanced renal cell carcinoma	442 / 444	some concern	conclusif	demonstrated 31 % decrease in progression or deaths (PFS) (PE) suggested 31 % decrease in PFS (extension)
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	avelumab plus axitinib
	JAVELIN Renal 101( PDL1>1%), 2019 N. Engl. J. Med. 2019; 380:1103-1115 Cancer Sci. 2020; 111:907-923 Nat Med 2020 Sep 7. Ann Oncol 2020 Aug;31(8):1030-1039. ESMO Open 2021 Apr 23;6(3):100101. NCT02684006	RCT	mRCC - L1 - PDL1 positive	Avelumab plus Axitinib	Sunitinib	patients with previously untreated advanced renal cell carcinoma (PDL1>1% population)	270 / 290	some concern	conclusif	suggested 31 % decrease in deaths (OS) (PE) demonstrated 39 % decrease in progression or deaths (PFS) (PE) suggested 38 % decrease in PFS (extension)